
- /
- Supported exchanges
- / F
BioXcel Therapeutics Inc (BX2 F) stock market data APIs
BioXcel Therapeutics Inc Financial Data Overview
BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get BioXcel Therapeutics Inc data using free add-ons & libraries
Get BioXcel Therapeutics Inc Fundamental Data
BioXcel Therapeutics Inc Fundamental data includes:
- Net Revenue: 2 403 K
- EBITDA: -104 299 000
- Earnings Per Share: -1
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-10
- EPS/Forecast: -1.08
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
BioXcel Therapeutics Inc News

BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
BioXcel Therapeutics Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential ...


BioXcel Therapeutics Strengthens Clinical Development Leadership to Advance Late-Stage Programs
BioXcel Therapeutics Vincent J. O’Neill, M.D., promoted to Executive Vice President, Chief of Product Development and Medical Officer Rajiv Patni, M.D., appointed Strategic Clinical Advisor to CEO...

BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
BioXcel Therapeutics Company to review BXCL502 and other potential emerging pipeline candidates Dr. Jeffrey Cummings to discuss agitation relief in Alzheimer’s disease and BXCL502 as a potential t...

7 Penny Stocks With Low Floats and High Short Interest
There are many ways to approach penny stocks, but one that has gained popularity in recent years focuses on stocks in this category that are prime candidates for a “short squeeze.” A typical shor...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.